There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lemaitre Vascular (LMAT – Research Report), Axsome Therapeutics (AXSM – Research Report) and Reata Pharmaceuticals (RETA – Research Report) with bullish sentiments.
Lemaitre Vascular (LMAT)
Barrington analyst Michael Petusky maintained a Buy rating on Lemaitre Vascular today and set a price target of $54.00. The company’s shares closed last Monday at $44.45.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of
Lemaitre Vascular has an analyst consensus of Moderate Buy, with a price target consensus of $54.00.
Axsome Therapeutics (AXSM)
Jefferies analyst Chris Howerton maintained a Buy rating on Axsome Therapeutics today and set a price target of $77.00. The company’s shares closed last Monday at $35.11.
According to TipRanks.com, Howerton has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $83.50, a 129.0% upside from current levels. In a report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $51.00 price target.
Reata Pharmaceuticals (RETA)
In a report released yesterday, Maury Raycroft from Jefferies maintained a Buy rating on Reata Pharmaceuticals, with a price target of $70.00. The company’s shares closed last Monday at $30.17, close to its 52-week low of $22.71.
Raycroft has an average return of
According to TipRanks.com, Raycroft is ranked #2486 out of 7918 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Reata Pharmaceuticals with a $58.25 average price target, a 60.7% upside from current levels. In a report issued on March 23, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $91.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LMAT:
- Analysts Conflicted on These Technology Names: Boeing (BA), HP (HPQ) and Phreesia (PHR)
- Univest Securities Keeps a Buy Rating on Alzamend Neuro (ALZN)
- Alarm (ALRM) Receives a Buy from Roth Capital
- Morgan Stanley Sticks to Its Hold Rating for Nextdoor Holdings (KIND)
- New Buy Rating for Snap (SNAP), the Technology Giant